亿胜

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC

2022.05.07

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting

2022.04.29

Date

Title

2021-02-24

Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease

2021-01-29

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

2020-11-23

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

2020-10-15

Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases

2020-08-25

Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

2020-08-18

Essex Bio-Technology Reports First Half 2020 Financial Results

2020-08-10

Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech

2020-04-30

Essex Bio-Technology Joins X-ZELL Seed+ Investment Round

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT